Prostate cancer brachytherapy. Experience of the branches of the National Medical Research Center of Radiology

Brachytherapy is one of the methods of radiotherapy allowing to deliver a highly effective radiation dose to a tumor through a minimally invasive intervention. Depending on the source, brachytherapy can be low- and high-energy. The article describes the main stages of development of prostate cancer brachytherapy both in Russia and abroad. The main methods of brachytherapy used in modern medicine are described. References to recommendations of the leading radiological organizations on low-energy brachytherapy are provided. The main indications and counterindications for brachytherapy for treatment of prostate cancer using low-energy sources are described. Summary data on the effectiveness of the method depending on prostate cancer prognosis are presented. The results of using low-energy brachytherapy at the branches of the National Medical Research Center of Radiology of the Ministry of Health of Russia are described.

1. State of oncological care in Russia in 2014. Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMIRTS” Minzdrava Rossii, 2015. 236 p. (In Russ.).

2. Kaprin A.D., Panshin G.A., Albitsky I.A. et al. New medical technology: Brachytherapy of (localized) prostate cancer. FS license No. 2009/218 from 27.07.2009. (In Russ.).

3. Tsyb A.F., Karyakin O.B., Biryukov V.A. et al. New medical technology: Intratissue radiotherapy (brachytherapy) of prostate cancer. FS license No. 2010/180 from 17.05.2010. (In Russ.).

4. Guidelines on Prostate Cancer – European Association of Urology. Available at: https://uroweb.org/guideline/prostatecancer/.

5. American Brachytherapy Society (ABS): Brachytherapy Guidelines. Available at: https://www.americanbrachytherapy.org/ guidelines/.

6. Merrick G.S., Butler W.M., Lief J.H., Dorsey A.T. Temporal resolution of urinary morbidity following prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000;47(1):121–8. PMID: 10758313.

7. Wallner K., Lee H., Wasserman S., Dattoli M. Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resection. Int J Radiat Oncol Biol Phys 1997;37(3):565–9. PMID: 9112454.

8. Hughes S., Wallner K., Merrick G. et al.. Preexisting histologic evidence of prostatitis is unrelated to postimplant urinary morbidity. Int J Cancer 2001;96:79–82. DOI: 10.1002/ijc.10351. PMID: 11992389.

9. Grann A., Wallner K. Prostate brachytherapy in patients with inflammatory bowel disease. Int J Radiat Oncol Biol Phys 1998;40(1):135–8. PMID: 9422569.

10. Merrick G.S., Butler W.M., Wallner K.E. et al. Permanent interstitial brachytherapy in younger patients with clinically organconfined prostate cancer. Urology 2004;64(4):754–9. DOI: 10.1016/j.urology.2004.04.054. PMID: 15491715.

11. Grimm P.D., Blasko J.C., Sylvester J.E. et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys 2001;51(1):31–40. PMID: 11516848.

12. Potters L., Morgenstern C., Calugaru E. et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 2005;173(5):1562–6. DOI: 10.1097/01.ju.0000154633.73092.8e. PMID: 15821486.

13. Stone N.N., Stone M.M., Rosenstein B.S. et al. Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy. J Urol 2011;185(2):495–500. DOI: 10.1016/j.juro.2010.09.099. PMID: 21167528.

14. Vargas C., Swartz D., Vashi A. et al. Longterm outcomes and prognostic factors in patients treated with intraoperatively planned prostate brachytherapy. Brachytherapy 2013;12(2):120–5. DOI: 10.1016/j.brachy.2012.08.002. PMID: 23062705.

15. Zelefsky M.J., Kuban D.A., Levy L.B. et al. Multi-institutional analysis of longterm outcome for stages T1–T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 2007;67(2):327–33. DOI: 10.1016/j.ijrobp.2006.08.056. PMID: 17084558.

16. Blasko J.C., Grimm P.D., Sylsvester J.E., Cavanagh W. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol 2000;57(3):273–8. PMID: 11104885.